INC Research Holdings, Inc. (SYNH)
(Delayed Data from NSDQ)
$47.27 USD
+0.56 (1.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $47.36 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.27 USD
+0.56 (1.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $47.36 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Syneos Health (SYNH) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Syneos Health (SYNH) reports better-than-expected earnings for the fourth quarter and strong performances by the Clinical Solutions and Commercial Solutions arms.
Syneos Health (SYNH) Q4 Earnings Beat Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 3.50% and 2.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health (SYNH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Internet of Medical Things (IoMT) Stocks to Buy for 2022
by Riya Anand
Stocks like Boston Scientific (BSX), Medtronic (MDT), DexCom (DXCM) and Syneos Health (SYNH) are evolving rapidly in the field of IoMT.
Why Is Syneos Health (SYNH) Down 4.1% Since Last Earnings Report?
by Zacks Equity Research
Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Syneos Health (SYNH) for Now
by Zacks Equity Research
Investors about optimistic about Syneos Health (SYNH) given its better-than-expected results as well as strong segmental performance during the third quarter.
Why Syneos Health (SYNH) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Syneos Health (SYNH) Q3 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Syneos Health (SYNH) reports better-than-expected results for third-quarter 2021 on strength in Clinical Solutions and Commercial Solutions arms driving the top line.
Syneos Health (SYNH) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 3.39% and 0.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health (SYNH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syneos Health's (SYNH) New Pact Boosts Tech-Driven Solutions
by Zacks Equity Research
Syneos Health's (SYNH) recent acquisition boosts the company's ability to deliver strategic insights and technology-enabled solutions that address the customers' most complex data challenges.
Here's Why You Should Retain Syneos Health (SYNH) For Now
by Zacks Equity Research
Investors are optimistic about Syneos Health (SYNH), given the strength in its Clinical Solutions business and notable partnership deals.
Syneos Health's (SYNH) New Buyout Boosts Clinical Solutions Arm
by Zacks Equity Research
Syneos Health (SYNH) acquisition of StudyKIK strengthens the former's ability to provide technology and insight-driven solutions.
Syneos Health (SYNH) Enhances Clinical Trials With New Pact
by Zacks Equity Research
Syneos Health (SYNH) recent partnership develops a more patient-centric travel experience, advances diversity and inclusion in clinical research.
Syneos Health (SYNH) Up 11.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Syneos Health (SYNH) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the Clinical Solutions and Commercial Solutions segments drove Syneos Health's (SYNH) top line.
Syneos Health (SYNH) Q2 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Syneos Health (SYNH) reported better-than-expected revenues for the second quarter of 2021 on strong segmental performance.
Syneos Health (SYNH) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 3.19% and 0.71%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health (SYNH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syneos' (SYNH) New Patient Consortium to Drive Innovation
by Zacks Equity Research
Syneos' (SYNH) Patient Voice Consortium incorporates patient perspective across wide range of communities to guide product development lifecycle.
Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Syneos Health (SYNH) registers sales uptick in its Clinical Solutions business on the back of favorable acquisition impacts and increased project start-up activities.
Syneos Health (SYNH) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 6.76% and 1.83%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health (SYNH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reasons to Hold on to Syneos Health (SYNH) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery of its operating segments and strategic partnerships.